Important considerations in the management of HR+, HER2-negative early breast cancer
ASCO 2023 Expert Report in HR positive, HER2 negative breast cancer by Catherine Harper-Wynne
Management of HR-Positive/HER2-Negative Early Breast Cancer: Taking Direction From the Updated Gu...
Recent Updates in HR-Positive/HER2-Negative Early Breast Cancer: A Deep Dive Into Understanding t...
Case Study: Treating HR-Positive and HER2-Negative Breast Cancer
Raising the Bar in HR+/HER2- Early Breast Cancer: CDK4 and 6 Inhibitors
Assessing Risk in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: How to Approach Ch...
Optimizing adjuvant treatment in HR+/HER2- early breast cancer
The Role of Biomarkers in HR-Positive/HER2-Negative Early Breast Cancer: From Clinical Analysis t...
Moving Away from Chemotherapy to Treat HR-Positive/HER2-Negative Metastatic Breast Cancer
Managing the Borderline-Risk Patient With Hormone Receptor-Positive/HER2-Negative Early Breast Ca...
Dr. Denduluri on Treatment Approaches in Early-Stage HR+/HER2- Breast Cancer
Understanding the Concerns and Challenges of Patients With HR-Positive/HER2-Negative EBC: Expert ...
First-line Therapy for HR-positive, HER2-negative, mBC
Dr. Meisel on Optimizing Genomic Assays in Early-Stage HR-Positive, HER2-Negative Breast Cancer
Optimizing treatment in patients with early-stage HER2-positive breast cancer
Adjuvant therapy for early stage ER-positive, HER2-negative invasive breast cancer
Current state of CDK4/6 inhibitors in metastatic HER2-negative breast cancer
Genomic Assays for Chemotherapy Decisions in ER-Positive/HER2-Negative Breast Cancer
Management of premenopausal HR+/HER2- breast cancer with micro-metastasis